RSS feeds
Get your Heartwire news and discussions/opinions on theheart.org delivered to you!

Subscribe to theheart.org’s RSS (Really Simple Syndication) feeds to get Heartwire news and other content delivered to your laptop or your desktop. Our feeds include headlines, summaries and links back to theheart.org for the full article. RSS feeds are free!

Why should you consider using an RSS feed?
RSS will simplify the way you access and read the news from theheart.org. It will save you time by automatically pulling for you fresh content from your favorite cardiology news site. You will not have to search for new items anymore on the subject that interests you the most.

How do you get an RSS feed?
You have two options. You may already have a browser which has a reader included—if you are using Firefox, Safari (for Mac) or Internet Explorer 7.

If not, you can use an RSS reader available on the web. Most are free and can be easily added as a plug-in to your browser’s navigation bar. Check iGoogle, NewsGator, Netvibes, or MyYahoo.

What our terms and conditions for using our feed?
We welcome you to use theheart.org RSS feeds. If you have a personal website or blog, we invite you to add any of our feeds to your page. However, please note that wherever you display content obtained from us, its source (from theheart.org) must be clearly identified. We reserve the right to restrict the use of our RSS feeds if the conditions outlined are not met. Commercial use of theheart.org feeds is strictly forbidden.


heartwire news
rssbut All heartwire news

   By clinical condition
rssbut ACS
rssbut Arrhythmia/EP
rssbut Brain/Kidney/Peripheral
rssbut Clinical/Imaging
rssbut Heart failure
rssbut Hypertension
rssbut Interventional/Surgery
rssbut Lipid/Metabolic
rssbut Prevention
rssbut Thrombosis risk


Comments
rssbut All comments


Blogs
rssbut All blogs
rssbut Topolog
rssbut Fellows' Corner
rssbut Publisher's Blog


button
Previews
Featured CME
Poll
Do you think it should be mandatory for new diabetes drugs to undergo cardiovascular outcome trials?
See: FDA advisory committee recommends cardiovascular safety studies for diabetes drugs
Yes
No